Moderna says Omicron-targeted COVID shot shows better response
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Caribou Biosciences to halt CAR-T programs, explore sale
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Argus Reiterates Buy Rating on Moderna (MRNA), 'Discounted price offers buying opportunity'
June 9, 2022 11:09 AM EDTArgus analyst John Eade reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We are maintaining our BUY rating on Focus List selection Moderna Inc. (NYSE: MRNA). The company develops therapeutics and... More
Moderna (MRNA) Trades at Low, Down 6.3%
June 9, 2022 10:54 AM EDTModerna (NASDAQ: MRNA) Trades at Low, Down 6.3%



